Document:

EX-10.1

 Exhibit 10.1 

June 7, 2018 
 John Walker 

 

	 	Re:	Employment Agreement 

 Dear John: 

This letter will confirm the terms and conditions of your continued employment with Zosano Pharma Corporation, a Delaware corporation (the
“Company”). This letter amends, restates, supersedes and replaces that certain Employment Letter Agreement dated as of August 9, 2017 by and between the Company (individually and as successor in interest to ZP Opco,
Inc.) and you. 
 1.    Position and Duties. Effective May 17, 2018 (the “Effective
Date”), you will continue to be the President and Chief Executive Officer of the Company. You will report to the Board of Directors of the Company (the “Board”). You agree to perform the duties of your positions
and such other duties as may reasonably be assigned to you from time to time by the Board. You also agree that, except as provided below, you will devote 100% of your business time, and your best efforts, business judgment, skill and knowledge to
the advancement of the business and interests of the Company and its Affiliates (as defined in Section 6) and to the discharge of your duties and responsibilities for them. Except to the extent the restrictions contained in Section 3 may
apply, nothing in this Agreement shall prohibit you from (a) serving on the Board of Directors of each of Vizuri Health Sciences LLC, the Lucile Packard Children’s Hospital Stanford and Packard Children’s Health Alliance and serving
on the Board of Trustees at The University of Puget Sound, (b) making and managing passive investments, and/or (c) engaging in religious, academic, charitable, political or other community or non-profit activities, in each case, in a
manner, and to an extent, that will not materially interfere with your duties to the Company. 
 2.    Compensation
and Benefits. During your employment, as compensation for the services performed by you for the Company and its Affiliates, the Company will provide you the following pay and benefits: 

(a)    Base Salary. Effective on the Effective Date, the Company will pay you a base salary at the rate of $500,000
per year, payable in accordance with the regular payroll practices of the Company and subject to increase from time to time by the Compensation Committee of the Board (the “Compensation Committee”) in its discretion. 

(b)    Bonus Compensation. During employment, you will be considered annually for a bonus. Your bonus target for
each year is an amount equal to 50% of your base salary as of the end of such year. The amount of any bonus awarded will be determined by the Compensation Committee in its discretion, and will be based on your performance and the performance of the
Company against goals established annually by the Compensation Committee. Any such bonus will be paid to you in a lump sum prior to March 15 of the year following the year in which your right to the bonus became vested. 

 John Walker 

June 7, 2018 
  Page
 2
 
  

 (c)    Stock Options. 

(i)    On May 17, 2018, the Compensation Committee granted you an incentive stock option to purchase 100,000 shares
(the “Option”) of common stock, $0.0001 par value per share, of the Company (“Common Stock”). 

(ii)    The Option (A) has an exercise price per share equal to the closing price per share of Common Stock on the
date of the grant, and (B) is subject to vesting requirements such that 1/48th of the total Option shares shall vest on the same day of each month following the date of grant with all Option
shares being vested on the fourth anniversary of the date of grant. 
 (iii)    Notwithstanding any other provision of
the Option or any other stock option or equity incentive award that is granted to you by the Company in the future (the “Outstanding Options”): (A) an amount equal to 25% of the Total Option Shares (as defined
below) shall vest upon termination of employment pursuant to the last sentence of Section 4(a) or the first sentence of Section 4(b); and (B) an amount equal to 100% of the Total Option Shares (as defined below) shall vest upon a
Constructive Termination Event (as defined in Section 5(b)). For purposes of this Section 2(c)(iii), the term “Total Option Shares” shall mean, as of any given day, the total amount of shares purchasable by, or
issuable to, you pursuant to any then Outstanding Option, without regard to the number of shares that are vested at such time pursuant to the terms of such Outstanding Options. 

(iv)    In the event that your employment hereunder is terminated and you continue to serve as a member of the Board, the
Outstanding Options shall continue to vest so long as you continue to serve as a member of the Company’s Board. 

(d)    Participation in Employee Benefit Plans. You shall be entitled to participate in any and all employee
benefit plans from time to time in effect for the full-time employees of the Company generally, but the Company shall not be required to establish any such program or plan. Such participation shall be subject to (i) the terms of the applicable
plan documents and (ii) generally applicable Company policies. The Company may alter, modify, add to or delete its employee benefit plans at any time as it, in its sole discretion, determines to be appropriate. 

(e)    Vacations. You will be entitled to three weeks of paid vacation per year, in addition to holidays observed
by the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the reasonable business needs of the Company. 

(f)    Business Expenses. The Company will pay or reimburse you for all reasonable business expenses incurred or
paid by you in the performance of your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as it may
specify from time to time. 

 John Walker 

June 7, 2018 
  Page
 3
 
  

 3.    Confidential Information and Restricted Activities. 

(a)    Confidential Information. During the course of your employment with the Company, you will learn of
Confidential Information (as defined in Section 6), and you may develop Confidential Information on behalf of the Company. You agree that you will not use or disclose to any Person (as defined in Section 6) any Confidential Information
obtained by you incident to your employment or any other association with the Company or any of its Affiliates, except as required by applicable law or for the proper performance of your regular duties and responsibilities for the Company. You
understand that this restriction shall continue to apply for three (3) years after your employment terminates, regardless of the reason for such termination. In addition, you agree to sign the Company’s standard form of invention
assignment agreement as a condition of your employment hereunder. 
 (b)    Protection of Documents. All
documents, records and files, in any media of whatever kind and description, relating to the business, present or otherwise, of the Company or any of its Affiliates, and any copies, in whole or in part, thereof
(the “Documents”), whether or not prepared by you, shall be the sole and exclusive property of the Company. You agree to safeguard all Documents and to surrender to the Company, at the time your employment terminates or
at such earlier time or times as the Board may specify, all Documents then in your possession or control. 

(c)    Non-Solicitation. You acknowledge that in your employment with the Company you will have access to
Confidential Information which, if disclosed, would assist in competition against the Company and its Affiliates, and that you will also generate good will for the Company and its Affiliates in the course of your employment. Therefore, you agree
that the following restrictions on your activities during and after the termination of your employment are necessary to protect the good will, Confidential Information and other legitimate interests of the Company and its Affiliates: While you are
employed by the Company and during the 12 months immediately following termination of your employment for whatever reason, you shall not, directly or through any other Person, (A) seek to persuade any employee of the Company or any of its
Affiliates to discontinue employment or (B) solicit or encourage any customer, distributor, vendor, or other business partner of the Company or any of its Affiliates or any independent contractor providing services to the Company or any of its
Affiliates to terminate or diminish its relationship with them. For purposes of the foregoing, the terms “employee,” “customer,” “distributor,” and
“vendor” shall also include any person or party who held such status during the immediately preceding six (6) months. 

 John Walker 

June 7, 2018 
  Page
 4
 
  

 (d)    Enforcement of Restrictions. In signing this letter
agreement, you give the Company assurance that you have carefully read and considered all the terms and conditions of this letter agreement, including the restraints imposed on you under this Section 3. You agree without reservation that these
restraints are necessary for the reasonable and proper protection of the Company and its Affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. You further agree
that, were you to breach any of the covenants contained in this Section 3, the damage to the Company and its Affiliates would be irreparable. You therefore agree that the Company, in addition to any other remedies available to it, shall be
entitled to preliminary and permanent injunctive relief against any breach or threatened breach by you of any of those covenants, without having to post bond. You also agree that the period of restriction in Section 3(c) shall be tolled and
shall not run during any period you are in violation thereof. You and the Company further agree that, in the event that any provision of this Section 3 is determined by any court of competent jurisdiction to be unenforceable by reason of its
being extended over too great a time, too large a geographic area or too great a range of activities, that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law. It is also agreed that each of the
Company’s Affiliates shall have the right to enforce all of your obligations to that Affiliate under this letter agreement, including without limitation pursuant to this Section 3. It is agreed and understood that the terms of this letter
agreement are severable, and that no breach of any provision of this letter agreement or any other purported violation of law by the Company shall operate to excuse you from the performance of your obligations under this Section 3. 

4.    Termination of Employment. Your employment under this letter agreement shall continue for no definite term
until terminated pursuant to this Section 4. 
 (a)    The Company may terminate your employment for Cause upon
written notice to you setting forth in reasonable detail the nature of the Cause (as defined below). The following, as determined by the Company in its reasonable judgment, shall constitute “Cause” for termination:
(i) your persistent and willful refusal to follow reasonable directives of the Board; (ii) gross negligence or willful misconduct in the performance of your duties and responsibilities to the Company or any of its Affiliates;
(iii) your material breach of this letter agreement or any other agreement between you and the Company or any of its Affiliates, which breach continues for more than 15 days after the Company gives you written notice which sets forth in
reasonable detail the nature of such breach; (iv) other conduct by you that is or could reasonably anticipated to be materially harmful to the business, interests or reputation of the Company or any of its Affiliates; or (v) your failure
to promptly and voluntarily resign as an employee, the President and the Chief Executive Officer of the Company if the Company asks you to do so after the Succession Date (as defined below) in connection with the election of another individual to be
the President and Chief Executive Officer and the Company takes no action at such time to remove you from the office of Chairman of the Board. The Company also may terminate your employment other than for Cause upon written notice to you.
“Succession Date” means the earlier to occur of (i) the date that the U.S. Food and Drug Administration approves the Company’s new drug application for M207 and (ii) December 31, 2019. 

 John Walker 

June 7, 2018 
  Page
 5
 
  

 (b)    You may terminate your employment for Good Reason (as defined
below) upon written notice to the Company setting forth in reasonable detail the nature of the Good Reason. The following shall constitute “Good Reason” for termination: (i) the Company’s failure to continue
you in the position of President and Chief Executive Officer of the Company with such duties typically associated with such position unless such failure occurs in connection with the election of another individual to be the President and Chief
Executive Officer of the Company after the Succession Date and the Company takes no action at such time to remove you from the office of Chairman of the Board; (ii) failure of the Company to provide you compensation and benefits in accordance
with the terms of Section 2, above, for more than ten (10) business days after notice from you specifying in reasonable detail the nature of such failure, except in connection with a decrease in salary affecting each senior management
employee of the Company in a proportionate manner; (iii) relocation of your principal place of employment to a location more than fifty (50) miles from the Company’s current headquarters in Fremont, California; or (iv) the
failure of the Company’s successor to assume the Company’s obligations under this Agreement upon a Change in Control. You may also terminate your employment other than for Good Reason upon 30 days’ written notice to the Company. 

(c)    In the event you become disabled during employment and, as a result, are unable to continue to perform
substantially all of your duties and responsibilities under this letter agreement, either with or without reasonable accommodation, the Company will continue to pay you your base salary and to provide you benefits in accordance with
Section 2(d) above, to the extent permitted by plan terms, for up to twelve (12) weeks of disability during any period of three hundred and sixty-five (365) consecutive calendar days. If you are unable to return to work after twelve
(12) weeks of disability, the Company may terminate your employment, upon notice to you. If any question shall arise as to whether you are disabled to the extent that you are unable to perform substantially all of your duties and
responsibilities for the Company and its Affiliates, you shall, at the Company’s request, submit to a medical examination by a physician selected by the Company to whom you or your guardian, if any, has no reasonable objection to determine
whether you are so disabled, and such determination shall for the purposes of this letter agreement be conclusive of the issue. If such a question arises and you fail to submit to the requested medical examination, the Company’s determination
of the issue shall be binding on you. 
 5.    Severance Payments and Other Matters Related to Termination. 

(a)    Involuntary Termination. In the event of termination of your employment by the Company other than for Cause,
or in the event of your termination of employment for Good Reason in either case outside the Change in Control period stated in Section 5(b), the Company will (i) continue to pay you your base salary in effect at the time of such
termination (disregarding any decrease that forms the basis of a resignation for Good Reason pursuant to Section 4(b)(ii)) for a period of twelve (12) months from and after the date of termination, (ii) an amount equal to the annual
bonus awarded to you in respect of the prior calendar year, such bonus severance to be paid in equal installments during the twelve (12) month period following the date of termination, and (iii) continue to provide you with group medical,
dental and vision insurance for a period of twelve (12) months from and after the date of your termination. The Company will also pay you on the date of termination any base 

 John Walker 

June 7, 2018 
  Page
 6
 
  

 
salary, bonus and other wages earned but not paid through the date of termination, and pay for any vacation time accrued but not used to that date. In addition, as provided in Section 2(c),
the vesting schedule for any stock options and other equity incentive awards outstanding on the date of termination will automatically accelerate so that 25% of any then unvested option shares and other equity incentive awards shall immediately vest
and become exercisable upon such termination. Except as set forth in clauses (ii) and (iii) of the first sentence of this Section 5(a), benefits shall terminate in accordance with the terms of the applicable benefit plans based on the
date of termination of your employment. 
 (b)    Involuntary Termination within One Year after Change in
Control. In the event of termination of your employment by the Company (or its successor) other than for Cause, or in the event of your termination of employment for Good Reason, in either case during the one (1)-year period following a Change
in Control (a “Constructive Termination Event”), the Company (or its successor) will, in lieu of any severance under Section 5(a) above, pay you, upon receiving the signed Employee Release pursuant to Section 5(c),:
(i) a lump sum severance payment equal to twenty-four (24) months of your base salary in effect at the time of such termination (disregarding any decrease that forms the basis of a resignation for Good Reason pursuant to
Section 4(b)(ii)), (ii) an amount equal to the annual bonus awarded to you in respect of the prior calendar year, and (iii) a lump sum cash amount equal to 229.56% multiplied by the total cost of the projected premiums for group
medical, dental and vision insurance for a period of twenty-four (24) months covering the period from and after the date of your termination. The Company (or its successor) will also pay you on the date of termination any base salary, bonus and
other wages earned but not paid through the date of termination, and pay for any vacation time accrued but not used to that date. In addition, as provided in Section 2(c), the vesting schedule for any stock options and other equity incentive
awards outstanding on the date of termination will automatically accelerate so that 100% of any then unvested option shares and other equity incentive awards shall immediately vest and become exercisable upon such termination. Except as set forth in
clauses (ii) and (iii) of the first sentence of this Section 5(b), benefits shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(c)    Severance Conditional Upon Release. Any obligation of the Company to provide you severance payments under
Sections 5(a) and 5(b) above shall be conditioned upon your signing a general release of claims in the form provided by the Company and reasonably acceptable to you (the “Employee Release”) within twenty-one (21) days after the date on which you receive such Employee Release and upon your not revoking the Employee Release thereafter. Except as set forth in Section 5(b) regarding lump sum payments,
all base salary and bonus severance payments will be payable in accordance with the normal payroll practices of the Company and will begin at the Company’s (or its successor’s) next regular payroll period following the effective date of
the Employee Release, but shall be retroactive to the date of termination. For the avoidance of doubt, no cash compensation that may be earned by you pursuant to employment or a consulting arrangement with a Person other than the Company during the
period of time that the Company (or its successor) is making payments to you pursuant to this Section 5 shall be credited toward the Company’s severance 

 John Walker 

June 7, 2018 
  Page
 7
 
  

 
obligations under this Section 5. Notwithstanding anything to the contrary contained in this letter agreement, in the event that at the time of your separation from service you are a
“specified employee,” as hereinafter defined, any and all amounts payable under this Section 5 in connection with such separation from service that constitute deferred compensation subject to Section 409A of the Internal Revenue
Code of 1986, as amended (“Section 409A”), as determined by the Company in its sole discretion, and that would (but for this sentence) be payable within six (6) months following such separation from service, shall
instead be paid on the date that follows the date of such separation from service by six (6) months. For purposes of the preceding sentence, “separation from service” shall be determined in a manner consistent with
subsection (a)(2)(A)(i) of Section 409A and the term “specified employee” shall mean an individual determined by the Company to be a specified employee as defined in subsection (a)(2)(B)(i) of Section 409A. 

(d)    Termination for Cause or Voluntary Termination. In the event of termination of your employment by the
Company for Cause or your termination other than for Good Reason, the Company will pay you any base salary and other wages earned but not paid through the date of termination and pay for any vacation time accrued but not used to that date. The
Company shall have no obligation to pay you any bonus compensation or severance payments. Except for any right you may have under the federal law known as “COBRA” to continue participation in the Company’s group health and dental
plans at your cost, benefits shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(e)    Survival of Certain Provisions. Provisions of this letter agreement shall survive any termination if so
provided in this letter agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation your obligations under Section 3 of this letter agreement. The obligation of the Company (or
its successor) to make severance payments to you under Section 5(a) or 5(b) above, and your right to retain such payments, are expressly conditioned upon your continued full performance of your obligations under Section 3 hereof. Upon
termination by either you or the Company, all rights, duties and obligations of you and the Company to each other shall cease, except as otherwise expressly provided in this letter agreement. 

6.    Definitions. For purposes of this letter agreement, the following definitions apply: 

“Affiliates” means all persons and entities directly or indirectly controlling, controlled by or
under common control with the Company, where control may be by management authority, equity interest or otherwise.  

“Confidential Information” means any and all information of the Company and its Affiliates that is not generally
available to the public. Confidential Information also includes any information received by the Company or any of its Affiliates from any Person with any understanding, express or implied, that it will not be disclosed. Confidential Information does
not include information that enters the public domain, other than through your breach of your obligations under this letter agreement. 

 John Walker 

June 7, 2018 
  Page
 8
 
  

 “Change in Control” means (A) the sale, lease,
exchange, transfer or other disposition of all or substantially all of the assets of the Company or its Affiliates, or (B) any merger, consolidation, acquisition of the Company, or other business combination or stock sale (other than a sale of
stock for capital raising purposes) that results in the holders of the outstanding voting securities of the Company immediately prior to such transaction beneficially owning or controlling immediately after such transaction less than a majority of
the voting securities of the Company or the surviving entity or the entity that controls such surviving entity. 

“Person” means an individual, a corporation, a limited liability company, an association, a partnership,
an estate, a trust or any other entity or organization, other than the Company or any of its Affiliates. 

7.    Conflicting Agreements. You hereby represent and warrant that your signing of this letter agreement and the
performance of your obligations under it will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to any covenants against competition or similar covenants or any court orders
that could affect the performance of your obligations under this letter agreement. You agree that you will not disclose to or use on behalf of the Company any proprietary information of a third party without that party’s consent. 

8.    Withholding. All payments made by the Company under this letter agreement shall be reduced by any tax or
other amounts required to be withheld by the Company under applicable law. 
 9.    Assignment. Neither you nor
the Company may make any assignment of this letter agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other parties; provided, however, that the Company may assign its rights and
obligations under this letter agreement without your consent to one of its Affiliates or to any Person with whom it shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its
properties or assets. This letter agreement shall inure to the benefit of and be binding upon you, the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns. 

10.    Severability. If any portion or provision of this letter agreement shall to any extent be declared illegal
or unenforceable by a court of competent jurisdiction, then the remainder of this letter agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not
be affected thereby, and each portion and provision of this letter agreement shall be valid and enforceable to the fullest extent permitted by law. 

 John Walker 

June 7, 2018 
  Page
 9
 
  

 11.    Miscellaneous. This letter agreement sets forth the entire
agreement between you and the Company and replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of your employment with the Company. This letter agreement may
not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and the Company. The headings and captions in this letter agreement are for convenience only and in no way define or describe the scope or
content of any provision of this letter agreement. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words
“without limitation.” This letter agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument. This is a California contract and shall be
governed and construed in accordance with the laws of the State of California, without regard to the conflict of laws principles thereof. Nothing in this letter agreement or any other Company agreement, policy, practice, procedure, directive or
instruction limits your ability to (a) file a charge or complaint with any governmental agency, governmental commission or other governmental authority (“Governmental Authority”), (b) report possible
violations of law or regulation to any Governmental Authority, (c) make other disclosures that are protected under the whistleblower provisions of applicable law or regulation, or (d) receive a whistleblower or other award from a
Governmental Authority for information provided to a Governmental Authority. You do not need permission from anyone at the Company or the Company’s legal counsel in order to take any of the actions described in the preceding sentence, and you
do not have to notify the Company that you have taken or intend to take any of these actions. In addition, nothing in this Agreement is intended to interfere with or restrain the immunity provided under 18 U.S.C. section 1833(b) for confidential
disclosures of trade secrets (x) to lawyers or government officials solely for the purpose of reporting or investigating a suspected violation of law or (y) in a sealed filing in court or another legal proceeding. 

12.    Notices. Any notices provided for in this letter agreement shall be in writing and shall be effective when
delivered in person or deposited in the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, or to such other
address as either party may specify by notice to the other actually received. 
 13.    No Non-Employee Director
Compensation. You acknowledge and agree that you remain ineligible to receive non-employee director compensation for your service as a member of the Board or as Chairman of the Board. 

* * * * * 

 John Walker 

June 7, 2018 
  Page
 10
 
  

 At the time this letter agreement is signed by you and on behalf of the Company, it will take
effect as a binding agreement between you and the Company on the basis set forth above. 
  

									
	ZOSANO PHARMA CORPORATION	 		 		 	EMPLOYEE:
					
	By:	 	/s/ Kleanthis Xanthopoulos	 		 		 	/s/ John Walker
		 	Name: Kleanthis Xanthopoulos	 		 		 	John Walker
		 	Title:   Director	 		 		 	
					
		 		 		 		 	Date signed: June 7, 2018Exhibit

 

Exhibit 10.1
TERRAFORM POWER, INC.
CLASS A COMMON STOCK PURCHASE AGREEMENT
THIS CLASS A COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of June 11, 2018 by and between TerraForm Power, Inc., a Delaware corporation (the “Company”), Orion US Holdings 1 LP, a Delaware limited partnership (“Orion”) and Brookfield BRP Holdings (Canada) Inc., an Ontario corporation (“BRP”, and together with Orion, the “Investors”).
RECITALS

WHEREAS, on February 6, 2018, the Company entered into a Support Agreement (as amended from time to time, the “Support Agreement”) with Brookfield Asset Management Inc. (“Brookfield”), pursuant to which Brookfield agreed that, if requested by the Company, Brookfield would provide a backstop to the Company for up to $400 million of shares of Class A common stock of the Company, par value $0.01 per share (the “Common Stock”) at a price per share equal to the five-day volume weighted average price of the shares of Common Stock ending the trading day prior to the Company’s announcement of the tender offer to acquire shares of Saeta Yield, S.A. (the “Backstop Price”);
WHEREAS, on May 28, 2018, the Support Agreement was amended to increase the size of the backstop to up to $650 million of shares of Class A common stock;
WHEREAS, the Backstop Price is $10.66 per share; 
WHEREAS, on June 4, 2018, the Conflicts Committee of the Board of Directors of the Company approved the Company’s exercise of the backstop pursuant to the Support Agreement; and
WHEREAS, pursuant to terms set forth in this Agreement, the Company desires to sell to the Investors, and the Investors desire to purchase from the Company, shares of Common Stock;
NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
SECTION 1
Purchase and Sale of Shares
1.1    Sale of Shares.  Subject to the terms and conditions hereof, the Company will i) issue and sell to Orion, and Orion will purchase from the Company, at the Closing (as defined below), for a total purchase price of $331,500,000.26 (the “Orion Purchase Price”), 31,097,561 shares of Common Stock (the “Orion Shares”), and ii) issue and sell to BRP, and BRP will purchase from the Company, at the Closing (as defined below), for a total purchase price of $318,499,991.68 (the “BRP Purchase Price” and together with the Orion Purchase Price, the “Aggregate Purchase Price”), 

29,878,048 shares of Common Stock (the “BRP Shares” and together with the Orion Shares, the “Shares”). 
1.2    Closing. The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures (the “Closing”) on June 8, 2018, or at such other time as agreed by both parties (the “Closing Date”).  At the Closing, the Company will cause the transfer agent and registrar for the Common Stock to reflect the issuance of the Shares to the Investors and, concurrently, the Investors shall pay the Aggregate Purchase Price by wire transfer in accordance with the Company’s instructions.
SECTION 2
Representations and Warranties of the Company
The Company hereby represents and warrants the following as of the Closing Date:
2.1    Organization and Good Standing and Qualifications. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware, with requisite power and authority to own or lease its properties and conduct its business as now being conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned or leased by it makes such qualification necessary, other than those in which the failure so to qualify or be in good standing would not have a Material Adverse Effect. For purposes of this Agreement, “Material Adverse Effect” shall mean any event or condition that would reasonably be likely to have a material adverse effect on the business, operations, properties, or financial condition of the Company and its consolidated subsidiaries, taken as a whole, or adversely affect in any material respect the ability of the Company to perform its obligations; provided, that none of the following shall constitute a “Material Adverse Effect”: the effects of conditions or events that are generally applicable to the capital, financial, banking or currency markets and the renewable energy industry, and changes in the market price of the Common Stock.
2.2    Authorization. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement; (ii) the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby and thereby and the issuance, sale and delivery of the Shares have been duly authorized by all necessary corporate action and no further consent or authorization of the Company, its Board of Directors and, if required, stockholders; and (iii)  the Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies, or indemnification or by other equitable principles of general application.
2.3    Valid Issuance of Shares. The issuance of the Shares has been duly authorized by all requisite corporate action.  When the Shares are issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, the Shares will be duly and validly issued and outstanding, fully paid, and nonassessable, and will be free of all liens and restrictions on 

transfer other than restrictions on transfer under applicable state and federal securities laws and any Investor shall be entitled to all rights accorded to a holder of shares of Common Stock.
2.4    No Conflict.  The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby and thereby do not and will not (i) contravene or conflict with the certificate of incorporation or bylaws of the Company, (ii) contravene or conflict with or constitute a material default under any law binding upon or applicable to the Company or (iii) contravene or conflict with or constitute a material default under any material agreement or judgment binding upon or applicable to the Company.
2.5    Consents.  Except for the consents that have been obtained on or prior to the Closing or filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by the Company in connection with (i) the execution and delivery by the Company of this Agreement, (ii) the performance by the Company of its obligations under this Agreement or (iii) the consummation by the Company of any of the transactions contemplated by this Agreement.
2.6    Compliance.  The Company is not, and the execution and delivery of this Agreement and the consummation of the transactions contemplated herewith will not cause the Company to be (i) in violation or default of any provision of any instrument, mortgage, deed of trust, loan, contract, (ii) in violation of any provision of any judgment, decree, order or obligation to which it is a party or by which it or any of its properties or assets are bound, or (iii) in violation of any federal, state or, to its knowledge, local statute, rule or governmental regulation, in the case of each of clauses (i), (ii) and (iii), which would have a Material Adverse Effect.
2.7    Capitalization.  As of June 1, 2018 (the “Reference Date”), a total of 148,086,027 shares of Common Stock were issued and outstanding, increased thereafter solely as set forth in the next sentence.  Other than in the ordinary course of business, the Company has not issued any capital stock since the Reference Date other than pursuant to (i) employee benefit plans and (ii) outstanding warrants or options.  The outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable, were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities
2.8    Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the representations, warranties and covenants made herein by the Investors, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may be issued and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Section 4(a)(2) thereof. The sale and issuance of the Shares pursuant to, and the Company’s performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of the Company, or (ii) entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other securities of the Company.

2.9    Transfer Taxes.  All stock transfer or other taxes (other than income taxes) which are required to be paid in connection with the sale and transfer of the Shares to be sold to Investor hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.
2.10    Investment Company.  The Company is not and, after giving effect to the offering and sale of the Shares, will not be an “investment company” as defined in the Investment Company Act of 1940, as amended.
2.11    Brokers.  No brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this Agreement.
2.12    Registration Rights.  The Company acknowledges and agrees that all Shares issued to Orion pursuant to this Agreement shall be “Registrable Shares” as defined in the Registration Rights Agreement, dated October 16, 2017 between the Company and Orion.
SECTION 3
Representations and Warranties of the Investor
The Investor hereby represents and warrants the following as of the Execution Date:
3.1    Experience.  Each Investor is experienced in evaluating companies such as the Company, has such knowledge and experience in financial and business matters that such Investor is capable of evaluating the merits and risks of such Investor’s prospective investment in the Company, and has the ability to bear the economic risks of the investment.
3.2    Investment.  Each Investor is acquiring the Shares for investment for such Investor’s own account and not with the view to, or for resale in connection with, any distribution thereof.  Each Investor understands that the Shares have not been and will not be registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein.  Each Investor further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares. 
3.3    Rule 144. Each Investor acknowledges that the Shares must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available.  Each Investor is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions.  In connection therewith, each Investor acknowledges that the Company will make a notation on its stock books regarding the restrictions on transfers set forth in this Section 3, and will transfer the Shares on the books of the Company only to the extent not inconsistent herewith and therewith.

3.4    Access to Information. Each Investor has received and reviewed information about the Company and has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the Company’s facilities.  Each Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of an investment in the Shares.  Each Investor is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, except for the statements, representations and warranties contained in this Agreement.
3.5    Authorization. This Agreement when executed and delivered by each Investor will constitute a valid and legally binding obligation of each Investor, enforceable in accordance with its terms, subject to:  (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief, and other equitable remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights.
3.6    Investor Status.  Each Investor acknowledges that it is either (i) an institutional “accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act (an “Institutional Accredited Investor”) or (ii) a “qualified institutional buyer” as defined in Rule 144A of the Securities Act, as indicated on Schedule A hereto, and each Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company.
3.7    No Inducement.  Each Investor was not induced to participate in the offer and sale of the Shares by the filing of any registration statement in connection with any public offering of the Company’s securities, and any Investor’s decision to purchase the Shares hereunder was not influenced by the information contained in any such registration statement.
3.8    No Conflicts. The execution, delivery and performance by each Investor of this Agreement do not and will not (i) contravene or conflict with the organizational documents of such Investor, (ii) contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to such Investor or (iii) contravene or conflict with or constitute a default under any material contract or other material agreement or judgment, order, writ, injunction, citation, award or decree of any nature binding upon or applicable to such Investor.
3.9    Consent. No consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by each Investor in connection with (i) the execution and delivery by such Investor of this Agreement, (ii) the performance by such Investor of its obligations under this Agreement or (iii) the consummation by such Investor of any of the transactions contemplated by this Agreement.

SECTION 4
Conditions to Investors’ Obligations at Closing
The obligations of the Investors under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, any of which may be waived in writing by the Investors (except to the extent not permitted by law):
4.1    No Injunction, etc.  No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by this Agreement.  No action or claim shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by any Investor.
4.2    Representations and Warranties.  The representations and warranties of the Company contained in Section 2 shall have been true and correct in all material respects on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.
4.3    Securities Laws.  The offer and sale of the Shares to any Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.
4.4    Authorizations.  All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.
SECTION 5
Conditions to the Company’s Obligations at Closing
The obligations of the Company to the Investors under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by each Investor:
5.1    No Injunction, etc.  No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by this Agreement.  No action or claim shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this 

Agreement to be rescinded following consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by any Investor.
5.2    Representations and Warranties. The representations and warranties of the Investors contained in Section 3 shall be true and correct in all material respects  on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.
5.3    Securities Law Compliance.  The offer and sale of the Shares to the Investors pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.
5.4    Authorizations.  All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.

SECTION 6

Resales
6.1    Restrictive Legend.  The certificates representing the Shares, when issued, will bear a restrictive legend in substantially the following form:
“THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 144.”
The legend set forth in this Section 6.1 and the related notation in the Company’s stock books shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the Shares or issue to such holder by electronic delivery at the applicable balance account at The Depository Trust Company, if (i) the Shares are registered for resale under the Securities Act, (ii) the Shares are sold or transferred in compliance with to Rule 144 and the Company has received such documents and other information as it shall have reasonably requested to demonstrate compliance of such transfer or sale with Rule 144, or (iii) the Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144.  Following Rule 144 becoming available for the resale of Shares, without the requirement for the Company to be in compliance with the current public information required under Rule 144, the Company shall (at the Company’s expense), upon the written request of Investor, cause its counsel to issue to the Company’s transfer agent a legal opinion authorizing the issuance of a 

certificate representing the Shares without any restrictive or other legends, if requested by such transfer agent.

SECTION 7

Miscellaneous
7.1    Governing Law.  This Agreement shall be governed in all respects by the laws of the State of New York as applied to agreements entered into and performed entirely in the State of New York by residents thereof.
7.2    Survival.  The representations, warranties, covenants and agreements made herein shall survive any investigation made by any Investor and the Closing.
7.3    Successors, Assigns.  Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.  This Agreement may not be assigned by any party without the prior written consent of the other parties hereto; except that any party may assign this Agreement to any third party that acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise.
7.4    Notices.  All notices and other communications required or permitted hereunder shall be in writing and shall be sent by facsimile (receipt confirmed) or mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger, addressed
if to the Company, at the following address:
  
TerraForm Power, Inc.
7550 Wisconsin Ave.  
Bethesda, MD  20814  
Attention:    General Counsel 
Telephone:    (240) 762-7700  
E-mail: ARocheleau@terraform.com 

if to Orion, at the following address:

Orion US Holdings 1 LP
181 Bay Street, Suite 300
Toronto, Ontario
M5J 2T3
Attention:    General Counsel
E-mail:        Jennifer.Mazin@brookfield.com

if to BRP, at the following address:

Brookfield BRP Holdings (Canada) Inc.
181 Bay Street, Suite 300
Toronto, Ontario
M5J 2T3
Attention:    General Counsel
E-mail:        Jennifer.Mazin@brookfield.com

or at such other address as any party shall have furnished to the other parties in writing.  All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, (iii) when sent, if sent by facsimile, with an acknowledgement of sending being produced by the sending facsimile machine or (iv) one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.
7.5    Expenses.  Each of the Company and the Investors shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby.
7.6    Counterparts.  This Agreement may be executed in counterparts, each of which shall be enforceable against the party actually executing the counterpart, and all of which together shall constitute one instrument.
7.7    Severability.  In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to any party.
7.8    Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof.  No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein.
7.9    Waiver.  The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.  None of the terms, covenants and conditions of this Agreement can be waived except by the written consent of the party waiving compliance.
[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first set forth above.
	
		
	 
	 

	 
	 

	TERRAFORM POWER, INC.

	 
	 

	 
	 

	By:
	/s/ Andrea Rocheleau

	 
	Name: Andrea Rocheleau

	 
	Title:  General Counsel

	 
	 

	 
	 

	 
	

	ORION US HOLDINGS 1 L.P., by its general partner ORION US GP LLC

	 
	 

	 
	 

	By:
	/s/ Julian Deschatelets

	 
	Name: Julian Deschatelets

	 
	Title:  Senior Vice President

	 
	

	BROOKFIELD BRP HOLDINGS (CANADA) INC.

	 
	 

	 
	 

	By:
	/s/ Jennifer Mazin

	 
	Name: Jennifer Mazin

	 
	Title: Senior Vice President and Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]